Aurinia announces U.K. marketing authorization of Lupkynis

Aurinia Pharmaceuticals announced that the U.K. Medicines and Healthcare products Regulatory Agency has granted the Great Britain marketing authorization of LUPKYNIS to treat adults with active lupus nephritis, a serious complication of systemic lupus erythematosus. "The MHRA authorization of LUPKYNIS for individuals with lupus nephritis in Great Britain, on the heels of the marketing authorization in the EU, further expands the availability of LUPKYNIS as a treatment option for people with lupus nephritis," said Peter Greenleaf, President and Chief Executive Officer, Aurinia. "Otsuka has been a valued partner in these efforts, and we are pleased to work with them to reach new patients."